<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542516</url>
  </required_header>
  <id_info>
    <org_study_id>HC524/04</org_study_id>
    <nct_id>NCT00542516</nct_id>
  </id_info>
  <brief_title>Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty</brief_title>
  <official_title>Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty: Hydroxyethyl Starch Versus Ringer's Lactate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently the most use solution to volemic reposition in hip replacement arthroplasty is the
      crystalloid solution. This trial intends to compare two different volemic replacements: HES
      and Ringer's lactate. This research has been analyzing hemodynamic parameters and the
      coagulation status before and after the pre-expansion with the solutions above mentioned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is randomized an blind to the physician who is analyzing the results.It has been
      select adults; both sex; ASA I and II. These patients must be submitted to hip arthroplasty
      replacement. The anesthesia technique is single shot spinal anesthesia. Primary endpoint:
      assessment alternative; technique replacement volemic with HES 130/04. Secondary endpoint:
      haemostatic abnormalities; blood loss; transfusion blood.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HES expansion plasmatic efficacy</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemostatic alterations</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hip Replacement Arthroplasty</condition>
  <arm_group>
    <arm_group_label>HES 130/04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-expansion with HES</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ringer's lactate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-expansion with Ringer's lactate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyethyl Starch</intervention_name>
    <description>Dosage: 30ml/kg; frequency: one time; duration: 60min</description>
    <arm_group_label>HES 130/04</arm_group_label>
    <arm_group_label>Ringer's lactate</arm_group_label>
    <other_name>Voluven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringer's lactate</intervention_name>
    <description>Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups</description>
    <arm_group_label>Ringer's lactate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients involved: adults, ASA I and II;

          -  Surgery: hip replacement arthroplasty.

        Exclusion Criteria:

          -  Allergy starch;

          -  Anemia;

          -  Dysfunction renal;

          -  Heart insufficiency;

          -  Morbid obesity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Otávio C Auler Junior, PhD/Chairman</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital das Clínicas - Medicine School of the University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Orthopedics and Traumatology of HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg. 2001 Apr;92(4):855-62.</citation>
    <PMID>11273914</PMID>
  </reference>
  <reference>
    <citation>Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, Bepperling F. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth. 2000 Dec;47(12):1207-15.</citation>
    <PMID>11132743</PMID>
  </reference>
  <reference>
    <citation>Haisch G, Boldt J, Krebs C, Kumle B, Suttner S, Schulz A. The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery. Anesth Analg. 2001 Mar;92(3):565-71. Retraction in: Anesth Analg. 2011 May;112(5):1225.</citation>
    <PMID>11226079</PMID>
  </reference>
  <reference>
    <citation>Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg. 2002 Sep;95(3):544-51, table of contents.</citation>
    <PMID>12198032</PMID>
  </reference>
  <reference>
    <citation>Boldt J, Suttner S. Plasma substitutes. Minerva Anestesiol. 2005 Dec;71(12):741-58. Review.</citation>
    <PMID>16288182</PMID>
  </reference>
  <reference>
    <citation>Mielke LL, Entholzner EK, Kling M, Breinbauer BE, Burgkart R, Hargasser SR, Hipp RF. Preoperative acute hypervolemic hemodilution with hydroxyethylstarch: an alternative to acute normovolemic hemodilution? Anesth Analg. 1997 Jan;84(1):26-30.</citation>
    <PMID>8988994</PMID>
  </reference>
  <reference>
    <citation>Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE, Prough DS, Baus D, Bepperling F, Warltier DC. Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology. 2007 Jun;106(6):1120-7.</citation>
    <PMID>17525586</PMID>
  </reference>
  <reference>
    <citation>Otsuki DA, Fantoni DT, Margarido CB, Marumo CK, Intelizano T, Pasqualucci CA, Costa Auler JO Jr. Hydroxyethyl starch is superior to lactated Ringer as a replacement fluid in a pig model of acute normovolaemic haemodilution. Br J Anaesth. 2007 Jan;98(1):29-37. Epub 2006 Nov 26.</citation>
    <PMID>17130138</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2007</study_first_posted>
  <last_update_submitted>February 18, 2009</last_update_submitted>
  <last_update_submitted_qc>February 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>adilson hamaji - supervisor anesthesia institute orthopedic USP</name_title>
    <organization>University São Paulo</organization>
  </responsible_party>
  <keyword>Hip Replacement Arthroplasty</keyword>
  <keyword>Hydroxyethyl Starch</keyword>
  <keyword>Hemodilution</keyword>
  <keyword>Hetastarch</keyword>
  <keyword>Colloids</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

